Exercise adds to bone drugs at the spine

Exercise is routinely recommended to build bone and stave off osteoporosis, while the medical mainstay for people who already have low bone mass is antiresorptive drug therapy. These two approaches are usually studied separately, which leaves an obvious practical question unanswered: if someone is already on medication, does training add anything on top, or does the drug effectively set a ceiling? The answer matters because loading the skeleton is effortful and time-consuming, and people want to know whether it is redundant once treatment starts. This review set out to test whether the combination produces greater gains in bone density than medication alone.

The authors ran a structured database search supplemented by hand searching of key journals and reference lists, looking for randomised controlled trials in adults with low bone mass that compared antiresorptive agents plus exercise against antiresorptive agents alone. The outcome of interest was change in lumbar spine bone mineral density, taken either as absolute change in grams per square centimetre or as relative change in percent, and pooled as a standardised mean difference using both fixed and random effect models. Trial quality was rated with the Jadad score, and publication bias was checked with funnel plots. Seven randomised controlled trials met the predetermined inclusion criteria.

The combined-intervention group gained significantly more lumbar spine bone mineral density than the group receiving antiresorptive agents alone, with a standardised mean difference of 0.55 (95% CI 0.36 to 0.75; overall effect Z-value 5.51; p < 0.00001). Subgroup analyses produced consistent results rather than contradicting the main effect, which supports the robustness of the pooled estimate. Funnel plots suggested only slight publication bias. Methodological quality was modest, with most included studies scoring 3 on the Jadad criterion. The review reports no data on fracture rates, other skeletal sites, or how long the added benefit persists.

The finding supports the intuitive but previously untested idea that drug therapy and mechanical loading act additively on the spine rather than one substituting for the other. It fits alongside the broader body of work showing exercise increases bone mass, and extends it to people already receiving pharmacological treatment. What it does not establish is whether the extra density translates into fewer broken bones, which is the outcome that actually matters clinically. The authors are explicit that more randomised trials with longer follow-up and larger samples are needed before the additive effect can be considered confirmed.

For adults with low bone mass, this is a reason to think that training is not made redundant by medication — the two appear to stack, at least at the lumbar spine. The size of the pooled effect is moderate and comes from a small set of trials of middling quality, so it should be held as a promising signal rather than a settled number. Bone density is also only a proxy: the review cannot tell you whether the additional gain prevents fractures. Any decision about medication itself sits with a clinician, but the evidence here points to exercise contributing something of its own.